ETRM—I don’t have data to back it up, but I would guess that a device is more likely than a drug to obtain FDA approval despite missing the primary endpoint in phase-3.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.